Financial Survey: Atrion (ATRI) and Its Rivals

Atrion (NASDAQ: ATRI) is one of 81 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare Atrion to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.

Valuation & Earnings

This table compares Atrion and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atrion $143.49 million $27.58 million 30.24
Atrion Competitors $993.07 million $73.31 million 169.44

Atrion’s rivals have higher revenue and earnings than Atrion. Atrion is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Atrion and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atrion 22.98% 18.34% 16.33%
Atrion Competitors -450.57% -32.65% -16.09%

Dividends

Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.9%. Atrion pays out 26.6% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.9% and pay out 30.5% of their earnings in the form of a dividend. Atrion has increased its dividend for 15 consecutive years. Atrion is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.

Institutional & Insider Ownership

59.1% of Atrion shares are owned by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 23.1% of Atrion shares are owned by company insiders. Comparatively, 12.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Atrion has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Atrion’s rivals have a beta of 0.96, suggesting that their average stock price is 4% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Atrion and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion 0 0 0 0 N/A
Atrion Competitors 282 1318 2693 100 2.59

As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 16.47%. Given Atrion’s rivals higher probable upside, analysts clearly believe Atrion has less favorable growth aspects than its rivals.

Atrion Company Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply